Phosphodiesterase 4 inhibitor activates AMPK-SIRT6 pathway to prevent aging-related adipose deposition induced by metabolic disorder

Rolipram is a selective phosphodiesterase 4 (PDE4) inhibitor that exerts a variety of effects, including anti-inflammatory, immunosuppressive, and anti-tumor effects. The aim of this study was to investigate the effect of rolipram on metabolic disorder and its underlying mechanisms. Metabolic disord...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhuoran, Liang, Yaru, Zhang, Lu, Zhang, Nannan, Liu, Qingfei, Wang, Zhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188481/
https://www.ncbi.nlm.nih.gov/pubmed/30227388
http://dx.doi.org/10.18632/aging.101559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188481/
https://www.ncbi.nlm.nih.gov/pubmed/30227388
http://dx.doi.org/10.18632/aging.101559

Ejemplares similares